Alexandra Drakaki - Concepedia

Author

Alexandra Drakaki

University of California, Los Angeles ORCID

Also Known As

A. Drakaki, Alexandra Drakaki, Drakaki Alexandra, Drakaki, Alexandra, Feldman, Tatyana

257

Publications

8.4K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles University of Washington Fred Hutch Cancer Center Emory University Dana-Farber Cancer Institute

About

Alexandra Drakaki is an author at University of California, Los Angeles specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	28	4.4K
2	Immunology	9	9	229
3	Health Sciences	5	5	133
4	Clinical Immunology	1	1	10
5	Nephrology	1	1	23

Alexandra Drakaki

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, The Lancet UrologyGenitourinary CancerMedicineFirst-line TreatmentCancer Treatment	2016	2.2K
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer Christophe Massard, Michael S. Gordon, Sunil Sharma, Journal of Clinical Oncology	2016	839
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, New England Journal of Medicine	2024	764
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, The Lancet Oncology UrologyVersus ObservationGenitourinary CancerMedicineMuscle-invasive Urothelial Carcinoma	2021	393
Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008 Nicholas M. Donin, Christopher P. Filson, Alexandra Drakaki, Cancer	2016	338
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform Allan J. Pantuck, Dong‐Keun Lee, Theodore Kee, Advanced Therapeutics UrologyArtificial Intelligence PlatformMedicineCancer ManagementPharmacology	2018	120
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial Aung Naing, Deborah J. Wong, Jeffrey R. Infante, The Lancet Oncology Surgical OncologyMedicinePathologyAdvanced Solid TumoursImmune Checkpoint Inhibitor	2019	117
MicroRNA Gene Networks in Oncogenesis Alexandra Drakaki, Dimitrios Iliopoulos Current Genomics	2009	99

Page 1